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68-70 weeks after vaccination. Intradermal gene ntation induced higher antibody titers than did direct gene uijection into skeletal muscle and did not cause local inflammation or necrosis. Compared with control animals, the geInected mice were resistant to challenge with a heterologous strain of influenza virus. These results indicate that the cells of the skin can take up and express free foreign DNA and induce celinlar and humoral immune responses against the encoded protein.
We suggest that DNA uptake by the skin-as ted lymphoid tissues may play a role in the induction of cytotoxic T cells against viruses and other intracellular pathogens.
The injection of free (naked) plasmid DNA (pDNA) into skeletal muscle can lead to protein expression and to the induction of cytotoxic T cells (CTL) and antibodies against the encoded protein antigens (1) (2) (3) (4) . Striated muscle is considered to be the only tissue that efficiently takes up and expresses pDNA in the absence of a viral vector or a physical carrier (5) . However, muscle is not considered to be a site for antigen presentation because it contains few if any dendritic cells, macrophages, and lymphocytes. The skin and mucous membranes are the anatomical sites where most exogenous antigens are normally encountered. The skin-associated lymphoid tissues contain specialized cells that enhance immune responses. The keratinocytes produce interleukin 1 and tumor necrosis factor a, which can activate lymphocytes, macrophages, and dendritic cells (6) . The Langerhans' cells of skin carry the antigen from the skin to the drining lymph nodes. Antigen-loaded Langerhans' cells are potent activators of naive T lymphocytes (7) . A special subset of circulating T lymphocytes (epidermotropic lymphocytes) homes to the skin and plays a critical role in cutaneous immunity (8) . The dendritic cells and macrophages of the dermis can also take up antigen and initiate immune responses. Therefore, the in vivo transfection of epidermal or dermal cells by DNA would be expected to provide an efficient route for gene immunization that mimics a physiologic response to infection.
In an attempt to overcome the apparent inability of skin cells to take up and express pDNA, gold microprojectiles have been used to physically deliver genes into the cytoplasm of skin cells (9, 10) . Recently, we fortuitously observed that the injection of pDNA into the skin could trigger a humoral immune response (11) . Because the needle passed through the skin, with inevitable intradermal (i.d.) leakage of some DNA, we reconsidered the possibility that skin cells might be capable of taking up free DNA, expressing the encoded protein, and initiating an immune response. The experiments reported here verify this hypothesis and raise the possibility that DNA uptake and processing by the skin-associatedlymphoid tissue may be an adaptive mechanism for the efficient induction of cellular immunity to viruses.
METHODS
Plasmd. The expression vector pRSV-NP contains the Rous sarcoma virus (RSV) long terminal repeat as a promoter element, the nucleoprotein (NP) gene from influenza strain A/PR/8/34 (HlNl), the simian virus 40 virus t-intron, and the simian virus 40 polyadenylylation site. The pCMV-NP plasmid is the same as pRSV-NP, except that the RSV promoter was replaced by the cytomegalovirus (CMV) MEl promoter-intron (1, 3 Fig. 1A . In transient transfection assays, the vectors produced similar amounts of NP protein, and the immune response induced by both plasmids was equivalent after i.m. injection (results not shown). However, the pCMV-NP vector (three injections of 15 pg of DNA at 2-week intervals) stimulated higher antibody responses than did the pRSV-NP vector (under the same conditions) after i.d. immunization (Fig. 1A) . This may reflect a promoter specificity in the transfected skin cells. Recently, the CMV promoter was shown to express the highest levels of a transgene product in different tissues in vivo when compared with other promoters, including RSV (13) .
To evaluate the long-term kinetics of anti-NP IgG response, serum samples of i.d.-injected mice (three injections of 15 pg of DNA at 2-week intervals) were analyzed serially for 68 weeks. All animals produced IgG, anti-NP antibodies that peaked initially 6 weeks after pCMV-NP injection and persisted through the 68th week without any drop in titer (Fig. 1B) .
To determine the minimal amount of pDNA necessary for i.d. vaccination, the animals were given a single injection of different doses of pCMV-NP, and antibody levels were assayed 3, 5, and 7 weeks afterward (Fig. 1C) . Three micrograms of pDNA was the lowest immunogenic dose. However, if the pCMV-NP was mixed with nonspecific carrier DNA (pUC19), as little as 0.3 pg of pCMV-NP was sufficient to induce an immune response (Fig. ID) . Antibody levels increased more quickly in mice injected with more DNA. However, at later time points, antibody titers were nearly equivalent in animals injected with 3-100 pg of pDNA.
To compare the anti-NP antibody response induced by genetic vaccination by the i.d. and the i.m. routes, mice were given a single injection of 1 pug and 10 pg of pCMV-NP i.d. and i.m. Antibody levels were assayed for 10 weeks afterward (Fig. 2) . The kinetics of the anti-NP antibody responses after i.d. and i.m. DNA vaccination were different. i.d. DNA vaccination yielded, in general, 4-fold higher antibody titers from the second through the tenth week after vaccination (mean endpoint titer 1:5120) than i.m. injection (mean endpoint titer 1:1280) at equivalent amounts (10 pg) of pDNA. CTL Responses. To determine if i.d. gene injection could induce a specific and long-lasting CTL response, mice were sacrificed 70 weeks after pCMV-NP injections (three injections of 15 pig of DNA at 2-week intervals), and their splenocytes were used to set up standard mixed lymphocyte cultures in the presence of a synthetic peptide representing the major H-2Kd-restricted CTL epitope on the NP protein (1, 3, 12) . The cultures were assayed for anti-NP CTL activity 6 days later using NP peptide-pulsed syngeneic P815 tumor cells as targets. Mixed lymphocyte cultures prepared from these animals displayed high levels of specific anti-NP cytolytic activity, reaching 50%-90% and 70%-100%o of specific Cr release at an effector-to-target ratio of 10/1 and 30/1, respectively. The same range of CTL activity was obtained 1 2 1 4 1 6 18 20 22 24 Day could still be amplified from the skin 5 mo after injection.
Immunohistochemical analyses with anti-NP antibody were done 3, 10, and 30 days after a single i.d. injection of 100 pg of pCMV-NP. NP expression was detected in discrete areas of the epidermis and in the upper layers of the dermis (Fig. 5) . Positive cells included keratinocytes, fibroblasts, and those with the morphologic appearance ofdendritic cells. NP expression in the epidermis and the dermis was greater at 10 days than at 3 days after pDNA injection. Thirty days after pDNA injection, the NP was detected mostly in the dermis; some residual expression remained in the outer epidermal layers. The tail muscles in all the animals and the skin from control tails were completely negative. There were no signs of inflammation in the skin of the pCMV-NP-injected animals. Thus, it appears that antigen is expressed in both the Protection from Viral Challenge. To determine whether i.d. DNA vaccination could protect animals from viral challenge, mice were injected three times at 2-week intervals with 15 pig of the pCMV-NP plasmid, which contains the NP gene from the A/PR/8/34 (HlNl) strain of influenza virus. Another group of animals were injected with a control plasmid (pnBL3). Two weeks after the last DNA injection, the animals were challenged with a LDqo dose of a heterologous influenza strain, A/HK/68 (H3N2). The survival data are shown in Fig. 3 . Five ofthe i.d. vaccinated mice, but only one of the control mice, survived influenza infection (P < 0.01). The level of protection after NP gene vaccination tends to vary. The protection seen in Fig. 3 is with the range that we and others (1, 3) have observed with i.m. vaccination.
Gene Expression in Skin. To determine the location of the injected plasmid, Southern blots of PCR-amplified DNA extracted from different tissues were done 3 mo after a single i.d. injection of 100 pg ofpCMV-NP. The NP-specific 555-bp fragment was detected at the injection site (tail) but not in other organs (Fig. 4) . In Proc. Nad. Acad Sci. USA 91 (1994) (8, 14, 15) .
Because DNA-transfected cells expressing neoantigens can persist for long periods, they may become targets for immune attack (11) . In principle, this can lead to local inflammation and to the cessation of antigen expression. The epidermis not only contains abundant antigen-presenting cells but also expresses high levels of lipocortin, a potent natural inhibitor of inflammation (16) . This combination may facilitate the initiation of immune responses by neoantigens, while restraining inflammatory responses. Indeed, leukocytes were not present at the epidermal sites of NP production 3, 10, and 30 days after gene administration.
In the natural state, most foreign antigens are first confronted at the skin or mucosa. In some respects, therefore, gene administration into the superficial skin mimics a normal state. However, it has not been appreciated previously that the cells of the skin can capture and express free pDNA. Indeed, one rationale for the "gene gun," which bombards cells with DNA-coated gold microspheres, is that it overcomes this physical barrier (9, 10, 13, 17) . But our results indicate that complicated procedures for i.d. gene vaccination are entirely unnecessary. We have recently observed that abrasion of the skin with a plastic tuberculin-testing device coated with free NP DNA induced a strong immune response (E.R. and D.A.C., unpublished results). It thus seems that i.d. DNA immunization does not require needle injection, as long as the DNA penetrates the cornified epithelium and reaches the skin-associated-lymphoid tissues or other viable skin cells.
Altogether, these results indicate that i.d. DNA immunization elicits strong and persistent humoral and cellular immune responses. The continuous expression of the neoantigen in the skin and its processing and presentation by the skin-associated-lymphoid tissues may reproduce a natural process. This mode of gene delivery resulted in longer lasting immune responses than are usually obtainable by protein vaccines and also induced the formation of cross-reactive CTL. It is well established that the Langerhans' and dendritic cells of the skin are specialized for the uptake and expression of protein antigens. In addition, antigen-presenting cells may be able to take up and express foreign DNA released by dying cells after viral infection. Such a mechanism would facilitate the induction of CTL responses against viruses, especially those that do not directly infect macrophages, dendritic cells, or other antigen-presenting cells, and insure that the major viral antigens enter the class I processing pathway.
It was originally thought that striated muscle cells were unique in their ability to take up and express free DNA in vivo (5, 18) . However, the intensity of expression of the NP antigen by epidermal and dermal cells exposed to free pDNA belies this interpretation. Instead, the data raise the possibility that the induction ofan immune response by exogenous DNA may be a basic biologic phenomenon in the skin and the skin-associated-lymphoid tissues.
